A Single Intra-articular Injection of aMAT vs PRP in Patients With OA of the Knee (LIPOJOINT)
A SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY OF A SINGLE, INTRA-ARTICULAR INJECTION OF AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT) VERSUS (VS) PRP IN PATIENTS WITH OSTEOARTHRITIS (OA) OF THE KNEE
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The clinical trial is a prospective, randomized, controlled, two-arm, single-blind study, involving 118 patients affected by symptomatic OA of the knee joint. Eligible subjects will be randomly allocated to one of the two treatment groups, with a 1:1 randomization ratio. Respectively, 59 patients treated with a single intra-articular injection of aMAT, and 59 patients treated with a single intra-articular injection of PRP.
The patients enrolled in the study will be treated according to the study protocol and followed after treatment with periodic visits and diagnostic imaging examinations, as Magnetic Resonance Imaging at twelve and twenty-four months follow-up and X-Ray, at three, six, twelve, and twenty-four months of follow-up.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Silvia Versari
- Phone Number: +39 02 37072408
- Email: silvia.versari@lipogems.eu
Study Contact Backup
- Name: Marco Tiana
- Phone Number: +39 02 37072408
- Email: marco.tiana@lipogems.eu
Study Locations
-
-
-
Bologna, Italy, 40136
- Recruiting
- Rizzoli Orthopaedic Institute
-
Contact:
- Maurilio Marcacci
- Email: m.marcacci@biomec.ior.it
-
Contact:
- Giuseppe Filardo
- Email: ortho@gfilardo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Patients provided written informed consent;
- Patients aged between 18 and 75 years;
- Knee symptomatic OA (Kellgren-Lawrence grade 1-4)
- Failure of conservative treatment for at least 3 months;
- Patients agreed to actively participate in the rehabilitation protocol and follow-up program;
- Male or female patients;
- Women of childbearing age had to use a proven method to prevent pregnancy, before the surgical treatment.
Exclusion Criteria
- Patients incapable to understanding and will;
- Patients participating in previous, concurrent or not, trials (ongoing or completed within three months);
- Patients surgically treated for the same defect within one year;
- Patients affected by malignancy;
- Patients affected by metabolic or thyroid disorders;
- Patients used to alcohol or drug (medication) abuse;
- Patients affected by synovitis;
- Varus or valgus misalignment exceeding 15°;
- Body Mass Index > 40;
- Patients with trauma within 6 months pre-operative.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)
injection of aMAT obtained with Lipogems® technology.
|
adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
|
|
Active Comparator: platelet-rich plasma (PRP)
single injection of platelet-rich plasma
|
injection of platelet-rich plasma
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: Time Frame: 24 months evaluation
|
Safety of the procedure, documenting characteristics and incidence of adverse events.(AE)
|
Time Frame: 24 months evaluation
|
|
clinical improvement documented with IKDC(International Knee Documentation Committee) score and KOOS (Knee Injury and Osteoarthritis Outcome Score)
Time Frame: Time Frame: 6 months evaluation
|
change in IKDC and KOOS score
|
Time Frame: 6 months evaluation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
stability of the clinical improvement documented with International Knee Documentation Committee (IKDC) score
Time Frame: Time Frame: 6, 24 months evaluation
|
Change in IKDC Subjective score from baseline to follow up
|
Time Frame: 6, 24 months evaluation
|
|
stability of the clinical improvement documented with Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Time Frame: 3,6, 12, 24 months evaluation
|
Change in KOOS score from baseline to follow up
|
Time Frame: 3,6, 12, 24 months evaluation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Silvia Versari, Lipogems International spa
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LIPOJOINT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.